Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tropoelastin is the soluble, monomeric precursor of elastin, a critical structural protein that imparts elasticity and resilience to tissues such as the skin, lungs, and vasculature. In the extracellular space, tropoelastin molecules are cross-linked by lysyl oxidase to form insoluble elastin fibers. As a therapeutic agent, recombinant tropoelastin is used in regenerative medicine and dermatology to promote wound healing, reduce scarring, and restore tissue elasticity. PancreaCell (a Leonhardt Ventures company) incorporates the stimulation of endogenous tropoelastin release into its bioelectric regenerative platform to facilitate tissue repair and extracellular matrix formation. Other developers have explored recombinant tropoelastin as an injectable or topical agent for aesthetic and surgical applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tropoelastin.